Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm
NCT06725121
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant (MacroTrans)
Downstaging of Hepatocellular Carcinoma with Macrovascular Invasion by Radiotherapy (SBRT or Y90) and Atezolizumab Plus Bevacizumab Followed by Liver Transplantation - a Prospective Trial
Sponsor: University Health Network, Toronto
Conditions
Downstaging Hepatocellular Carcinoma (HCC) Liver Transplant Surgery Macrovascular Invasion
Updated 1 time since 2025 Last updated: Dec 11, 2024 Started: Dec 31, 2024 Primary completion: Jun 30, 2031 Completion: Jun 30, 2034
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1/PHASE2 trial investigates Downstaging and Hepatocellular Carcinoma (HCC) and is currently actively recruiting participants. University Health Network, Toronto leads this study, which shows 1 recorded version since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- University Health Network, Toronto
Data source: University Health Network, Toronto
For direct contact, visit the study record on ClinicalTrials.gov .